Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GUANETHIDINE MONOSULFATE vs ISMELIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Guanethidine is an adrenergic neuron blocking agent that inhibits the release of norepinephrine from postganglionic sympathetic nerve terminals by displacing it from storage vesicles. It also depletes norepinephrine stores, leading to reduced sympathetic tone and vasodilation.
Guanethidine inhibits norepinephrine release from postganglionic sympathetic nerve terminals and depletes norepinephrine stores, leading to reduced sympathetic tone and vasodilation.
Hypertension (oral),Management of hypertensive emergencies (parenteral),Reflex sympathetic dystrophy (off-label),Glaucoma (ophthalmic use)
Severe hypertension,Hypertensive crisis (off-label)
Initial: 10 mg orally once daily. Increase in increments of 10 mg at weekly intervals until adequate response. Usual maintenance: 25-50 mg once daily. Maximum: 100 mg daily.
Initiate at 10 mg orally twice daily; increase gradually by 10 mg increments every 1-2 weeks. Typical maintenance dose 25-50 mg twice daily; maximum 150 mg/day.
5-10 days (prolonged due to extensive tissue binding); requires dose adjustment in renal impairment.
Terminal half-life of 5-7 days; allows once-daily dosing. Clinical context: long half-life leads to cumulative effects and prolonged washout.
Primarily hepatic via monoamine oxidase (MAO) with subsequent conjugation; some drug is excreted unchanged in urine. Active metabolite (2,3-dihydroxybenzylguanidine) may contribute to effects.
Metabolized primarily by hepatic N-oxidation and N-dealkylation; metabolites are excreted renally.
Renal: ~50% unchanged; some biliary/fecal.
Primarily renal excretion of unchanged drug (40-50%) and metabolites; remainder is biliary/fecal. Exact percentages not well defined.
~10%; mainly albumin.
Less than 10% bound to plasma proteins.
~200 L/kg (extensive tissue binding, concentrating in adrenergic neurons).
Approximately 0.03-0.06 L/kg; small Vd consistent with limited tissue distribution.
Oral: 3-30% (highly variable, extensive first-pass metabolism).
Oral bioavailability variable, approximately 30-50% due to first-pass metabolism.
GFR 30-50 m L/min: Reduce dose by 25-50%. GFR 10-29 m L/min: Reduce dose by 50-75%. GFR <10 m L/min: Avoid use or administer at 25% of normal dose.
GFR 30-59 m L/min: reduce dose by 50%. GFR 15-29 m L/min: reduce dose by 75%. GFR <15 m L/min: contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use (risk of hypotension and accumulation).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Initial: 0.2 mg/kg orally once daily. Titrate weekly by 0.2 mg/kg. Maximum: 3 mg/kg/day or 100 mg/day, whichever is less.
0.2 mg/kg/day orally divided every 12 hours; titrate weekly by 0.2 mg/kg/day. Maximum 5 mg/kg/day or 150 mg/day.
Initiate at 5 mg orally once daily due to increased sensitivity. Titrate slowly (2-week intervals) to avoid orthostatic hypotension and falls.
Initiate at 5 mg orally twice daily; increase by 5 mg increments every 1-2 weeks. Maximum 75 mg/day due to increased sensitivity and orthostatic hypotension risk.
WARNING: Orthostatic hypotension, syncope, and bradycardia can occur, especially with rapid dose escalation. Patients should be warned about postural hypotension and encouraged to report symptoms. Avoid use in patients with pheochromocytoma or congestive heart failure.
May cause severe orthostatic hypotension, syncope, and bradycardia. Use with caution in patients with cerebrovascular or coronary insufficiency.
May cause severe orthostatic hypotension, syncope, bradycardia, diarrhea, sexual dysfunction, and sodium/water retention. Use with caution in renal impairment, coronary artery disease, and cerebrovascular insufficiency. Abrupt discontinuation may cause rebound hypertension. Potentiation by MAO inhibitors or anesthetics.
Orthostatic hypotension is common and may be severe; patients should avoid sudden posture changes. Use cautiously with beta-blockers, MAOIs, and volatile anesthetics. May exacerbate bronchial asthma. Discontinue 2 weeks before elective surgery due to interaction with anesthetics. Do not use with MAOIs or pheochromocytoma.
Pheochromocytoma, congestive heart failure (especially due to increased cardiac output), concurrent use with MAO inhibitors, severe renal impairment, and known hypersensitivity.
Absolute: Pheochromocytoma, concurrent use or recent use of MAOIs, catecholamine-depleting agents. Relative: Severe cerebrovascular insufficiency, myocardial infarction, asthma, renal impairment.
Avoid tyramine-rich foods (e.g., aged cheese, cured meats, fermented products) as guanethidine may potentiate pressor effects. Limit alcohol intake due to additive hypotensive effects. No other significant food interactions known.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) due to risk of hypertensive crisis. Monitor alcohol intake as it may exacerbate hypotension. Grapefruit juice may affect metabolism; avoid concurrent use.
Guanethidine is an adrenergic neuron blocking agent. Data on human pregnancy are limited. Animal studies have not shown teratogenicity. However, due to its pharmacological action, use in the first trimester should be avoided unless clearly needed. In second and third trimesters, risk is considered low; however, fetal bradycardia and hypotension may occur with maternal use near term.
Ismelin (guanethidine) is contraindicated in pregnancy, particularly in the first trimester due to potential teratogenic effects. Animal studies have shown fetal abnormalities, and there are no adequate human studies. Risk cannot be excluded.
Guanethidine is excreted into breast milk in small amounts. The M/P ratio is approximately 0.1. At maternal therapeutic doses, the estimated daily infant dose is less than 10% of the maternal weight-adjusted dose, which is considered compatible with breastfeeding. However, monitor infant for hypotension, bradycardia, and diarrhea.
Guanethidine is excreted in breast milk; the M/P ratio is unknown. Due to potential for adverse effects in the nursing infant, including hypotension and bradycardia, breastfeeding is not recommended during therapy.
Pregnancy may reduce the antihypertensive efficacy of guanethidine due to increased plasma volume and altered catecholamine sensitivity. Dose adjustments may be required, but specific pharmacokinetic changes are not well characterized. Use with caution and titrate based on clinical response.
No specific dose adjustments are recommended as use is contraindicated. If required in exceptional circumstances, cautious dose reduction may be needed due to increased blood volume and altered pharmacokinetics in pregnancy, but evidence is lacking.
Guanethidine monosulfate is an adrenergic neuron blocking agent used primarily for severe hypertension unresponsive to other agents. Its use is limited due to orthostatic hypotension, syncope, and drug interactions. Avoid concurrent use with MAOIs, tricyclic antidepressants, and sympathomimetics as they can reverse or block its effect. Monitor for orthostatic BP changes; advise patient to rise slowly. Discontinue gradually to avoid rebound hypertension.
ISMELIN (guanethidine) is a potent antihypertensive that causes sympathetic blockade. Use with extreme caution in patients with pheochromocytoma, as it may precipitate hypertensive crisis. Monitor for orthostatic hypotension, especially in elderly. Avoid co-administration with MAOIs; discontinue MAOI at least 2 weeks prior. May cause bradycardia and diarrhea. Do not use in patients with heart failure or recent MI.
Take this medication exactly as prescribed, usually once daily.,Do not stop taking this medication suddenly; withdrawal can cause a dangerous rise in blood pressure.,Avoid alcohol, as it can worsen orthostatic hypotension.,Stand up slowly from sitting or lying down to prevent dizziness and fainting.,Inform your doctor if you experience fainting, severe dizziness, or palpitations.
Take exactly as prescribed; do not stop suddenly as it may cause severe rebound hypertension.,Avoid sudden changes in posture; rise slowly from sitting or lying to prevent dizziness.,Report any fainting, slow heart rate, or severe diarrhea to your doctor.,Avoid alcohol and over-the-counter cold or allergy medications.,Do not drive if you feel dizzy; this medicine may impair your ability to perform hazardous tasks.,Inform all healthcare providers you are taking guanethidine.
"Cyclothiazide, a thiazide diuretic, enhances the hypotensive effect of guanethidine, a sympatholytic antihypertensive agent, by promoting sodium and volume depletion and possibly by directly enhancing vascular responsiveness to catecholamines. This additive effect can lead to excessive blood pressure reduction, orthostatic hypotension, and increased risk of syncope, particularly during initial therapy or dose adjustments."
"Treprostinil, a prostacyclin analog, causes direct vasodilation and inhibits platelet aggregation. Guanethidine, an adrenergic neuron blocker, reduces sympathetic output by depleting norepinephrine stores. The combination produces additive hypotensive effects, potentially leading to severe hypotension, syncope, or orthostatic hypotension, especially during dose titration or upright posture."
"Sildenafil potentiates the hypotensive effect of guanethidine by enhancing cyclic guanosine monophosphate (cGMP)-mediated vasodilation, leading to an increased risk of profound hypotension, syncope, and cardiovascular collapse. Guanethidine depletes norepinephrine stores in sympathetic nerve endings, reducing compensatory adrenergic responses, while sildenafil inhibits phosphodiesterase type 5 (PDE5), prolonging the vasodilatory action of nitric oxide. This synergistic effect can result in a rapid and exaggerated drop in blood pressure, particularly upon initiation of therapy or dose escalation."
No interactions on record
Common clinical questions about GUANETHIDINE MONOSULFATE vs ISMELIN, answered by our medical review team.
GUANETHIDINE MONOSULFATE is a Adrenergic Neuron Blocker Antihypertensive that works by Guanethidine is an adrenergic neuron blocking agent that inhibits the release of norepinephrine from postganglionic sympathetic nerve terminals by displacing it from storage vesicles. It also depletes norepinephrine stores, leading to reduced sympathetic tone and vasodilation.. ISMELIN is a Adrenergic Neuron Blocker Antihypertensive that works by Guanethidine inhibits norepinephrine release from postganglionic sympathetic nerve terminals and depletes norepinephrine stores, leading to reduced sympathetic tone and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GUANETHIDINE MONOSULFATE and ISMELIN depend on the specific clinical indication. These are both Adrenergic Neuron Blocker Antihypertensive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GUANETHIDINE MONOSULFATE is: Initial: 10 mg orally once daily. Increase in increments of 10 mg at weekly intervals until adequate response. Usual maintenance: 25-50 mg once daily. Maximum: 100 mg daily.. The standard adult dose of ISMELIN is: Initiate at 10 mg orally twice daily; increase gradually by 10 mg increments every 1-2 weeks. Typical maintenance dose 25-50 mg twice daily; maximum 150 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GUANETHIDINE MONOSULFATE and ISMELIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GUANETHIDINE MONOSULFATE is classified as Category C. Guanethidine is an adrenergic neuron blocking agent. Data on human pregnancy are limited. Animal studies have not shown teratogenicity. However, due to its pharmacological action, . ISMELIN is classified as Category C. Ismelin (guanethidine) is contraindicated in pregnancy, particularly in the first trimester due to potential teratogenic effects. Animal studies have shown fetal abnormalities, and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.